|

Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients

RECRUITINGPhase 2Sponsored by Tanta University
Actively Recruiting
PhasePhase 2
SponsorTanta University
Started2025-03-01
Est. completion2026-03-20
Eligibility
Age18 Years – 65 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06863376

Summary

Nonalcoholic fatty liver disease (NAFLD) is a global public health concern, and the leading cause of chronic liver disease, especially in developed countries. NAFLD is characterized by lipid accumulation in the liver not attributed to other causes. Lifestyle interventions, including dietary modification and exercise, remain the cornerstone of NAFLD treatment. Pharmacological treatments aimed primarily at improving liver disease should generally be limited to those with biopsy-proven NASH and fibrosis.

Eligibility

Age: 18 Years – 65 YearsHealthy volunteers accepted
Inclusion Criteria:

* Either male or female adult patients (\>18 years) with fatty liver diagnosis by using upper abdominal ultrasound echography

Exclusion Criteria:

* Pregnant and/or lactating women
* Excessive alcohol use (defined as an average alcohol intake \> 30 g per day in men and \> 20 g per day in women)
* Other etiology of chronic liver diseases such as viral hepatitis, drug-induced hepatitis, autoimmune hepatitis.
* patients suffering from chronic kidney disease, and hyper/hypoparathyroidism
* Hypersensitivity to carbocistiene.

Conditions2

Liver DiseaseNon Alcoholic Fatty Liver Disease

Browse More Trials

Liver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.